´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26±³À°ÀÏÀÚ : 2023-02-26
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ
±³À°ÁÖÁ¦ :
Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ½ÅÀåÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
ksn@ksn.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 160,000¿ø
ºñ°í BRC (ÀüÀÏ) + ARC (3/26):160,000 ¿ø, BRC (1ÀÏ) + ARC (3/26) 120,000 ¿ø BRC (1ÀÏ): 80,000 ¿ø, ¸¸65¼¼ ÀÌ»ó ȸ¿ø, Çлý:¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:00~09:30 Basic renal pathology and evaluation of primary glomerular disease ±Ç±â¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:30~10:00 An update on the management of IgA nephropathy °¼®ÈÖ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:00~10:30 Immunoglobulin- and complement-mediated glomerular diseases with an MPGN pattern of injury ¹Ú¼±Èñ(°æºÏÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:30~11:00 Overview of the pathogenesis and treatment of ANCA-associated GN (ARC ¿¬°è °ÀÇ) È«À¯¾Æ(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 02-26 11:00~11:10 Break ()
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:10~11:40 How to use SGLT2 inhibitor and GLP-1 receptor agonist in diabetic kidney disease (ARC ¿¬°è °ÀÇ) ±æÈ¿¿í(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:40~12:10 Pathophysiology of diabetic kidney disease ¹®ÁÖ¿µ(°æÈñÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 12:10~12:40 Optimal treatment of dyslipidemia in diabetic kidney disease À¯ÅÂÇö(¿¬¼¼ÀÇ´ë)
½Ä»ç 02-26 12:40~13:30 Lunch Break ()
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 13:30~14:00 Evaluation for resistant hypertension in advanced CKD patients ÀÌÁ¤È¯(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:00~14:30 Treatment of osteoporosis in CKD ±èÁ°æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:30~15:00 Optimal management of anemia: EPO, iron, and new therapeutics °í°Áö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:00~15:30 Hypertension management in kidney transplant recipients Á¤Á¾Ã¶(¼¿ïÀÇ´ë)
ÈÞ½Ä 02-26 15:30~15:40 Break ()
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:40~16:10 HDF vs. expanded hemodialysis (ARC ¿¬°è °ÀÇ) ÀÌ¿µ±â(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:10~16:40 Flow related complication of arteriovenous fistula (ARC ¿¬°è °ÀÇ) ¹ÚÈƼ®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:40~17:10 How should we change the PD prescription when adequacy targets are not met? ±Ç¼ø±æ(ÃæºÏÀÇ´ë)